Africa and South America. The prevalence of the most carriers is seen in Cyprus (14%), Saardinia (10%) and Southeast regions of Dinia (10%) and Southeast Asia. A high frequency of beta thalassemia gene in these areas due to natural selection against malaria is Plasmodium falciparum (3) . The immigrant populations and marriage between different ethnic groups causes thalassemia to be common between all countries, even countries in northern Europe where thalassemia did not previously there. It is estimated that about 1.5 percent of the world population are thalassemia carriers, with about 60 000 people marked the birth annually; the majority of other are in developing countries (4) . According to the Thalassemia International Federation assessment, only about 200 000 patients with thalassemia major are alive and registered and regularly receive treatment in all over world (5) . Our country has a large number of cases is affected beta-thalassemia major; its prevalence is various in different geographical areas. The highest prevalence of β-thalassemia has been reported around the Caspian Sea and the Persian Gulf by more than 10%. The prevalence of this disorder in other areas is between 8-4% (6) .
Etiology
More than 200 mutations have been reported, the majority of mutations point are in beta-globulin gene areas. Beta globin gene deletions are not common; β-globin chain reduce or don't product due to β-globin gene mutations. A mutation causes a defect in the promoter activity, processing of RNA, translated or reduced instability of MRNA. Despite the great variety of mutations, only 20 of them result 80% of thalassemia (7, 8) . Gene modulators defined as genetic variants, which lead to differences in diseases phenotype. In homozygous beta thalassemia early genetic modifiers are effective clinical severity, which reduces the imbalance of globin chains, so they cause milder form of thalassemia. To inheritance of alpha thalassemia simultaneous or some genetic factors causing sustain production globin chains, (HbF) in adults (9) .
Various forms of thalassemia
Thalassemia can be divided into two types, alpha thalassemia and beta thalassemia ( Table 1 ). Given that the prevalence of beta thalassemia major patients is greater than alpha thalassemia patients in Iran respectively, therapeutic purposes focused on beta thalassemia major.
Alpha thalassemia
Alpha thalassemia is one of the most common hemoglobin disorders in the world which is more prevalent in parts of Africa, Southeast Asia and the Middle East (14) . Alpha globin gene cluster has a length of about 30 kb on chromosome 16 and inherited by four gene locus. Alpha thalassemia studied; show that the disease is largely due to the removal of changeable pieces from one or two alpha genes at the molecular level (15) . Two fragments of alpha globin gene α2 and α1 in analog two loci on the same chromosome replaced very similar to the two units are 4 kb, the same sequences are separated by nonidentical elements (16) . In fact recombination between alleles that could remove genes that to be one of the mechanisms responsible for decreasing the alpha chain synthesis in alpha thalassemia. The outcome disease severity depends on the number of genes involved in the final. If patient to be missing one of alpha gene release, α + ℎ 1,if missed two alpha genes transvers release homologous α + ℎ 1 + that in this form patient are also asymptomatic or associated with intermediate anemia but most of them have microcytic red blood cells (MCV <80fL). In case remove three alpha genes, this is hemoglobin H disease that patient shows intermediate thalassemia with intermediate anemia (17) . Whereas, deletion of each four genes lead to Hydrops Fetalis disease that is associated with intrauterine fetal death. More than 95% of alpha thalassemia is kind of elimination. The most common type of elimination alpha that the two genes are deleted referred to Southeast Asian variety (--SEA), Mediterranean (--MED), (α) 20.5) and the Philippines (--FIL). The most common single gene is removed, referred to (-α 3.7) and (-α 4.2) (18).
Beta thalassemia
Thalassemia syndromes are a group of inherited blood disorders caused by the decrease or absence of betaglobin chain synthesis will be determined with decrease in erythrocyte hemoglobin, decreased production of erythrocytes and anemia. More thalassemia is inherited as recessive autosomal. According to the clinical and laboratory diagnostic, three types of beta thalassemia defined: Beta thalassemia major, Beta thalassemia intermedia and Beta thalassemia minor (19).
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Beta thalassemia major
Thalassemia major clinical symptoms appear between 6 and 24 month after birth. Babies with thalassemia major will suffer nutritional problems, diarrhea, irritability, frequent bouts of fever, abdominal distention and a progressive increase in the size of spleen and liver (20) . So skeletal changes including changes in the long bones of the leg and craniofacial changes is seen in patients. In fact a regular blood transfusions can maintain hemoglobin levels in the range of 5.9 to 5.10 grams per deciliter in patients and grow up is close to normal until about 10 to 12 years (21). The patients, who receive blood, may involve complications of iron overload in the tissues. Complications of iron overload in children include delayed growth and sexual maturation. The next complications of iron overload including heart damage Myocardiopathy and rarely, arrhythmia, liver (fibrosis and cirrhosis), endocrine glands (diabetes), hypogonadism, parathyroid and thyroid insufficiency (22) . Complications consequent contamination blood transfusion cause transmit hepatitis B virus that and C, human immunodeficiency virus. The risk of hepatocellular carcinoma in patients with infectious liver and iron overload are greater eventually these patients die due to cirrhosis of the heart muscle caused by iron deposition in the heart (23, 24) .
Beta-thalassemia intermedia
Symptoms of people beside thalassemia major are determined later, they have milder anemia and do not need to regular blood transfusion. At one end of the spectrum of clinical symptoms will be displayed between the ages of 2 to 6 years in these patients (10) . Although, they can survive without regular blood transfusions. But suffer from a lack of sufficient growth. At the other end of the spectrum of disease, does not show specific symptoms except mild anemia into adulthood. In general, patients with thalassemia intermedia, hypertrophy and increased erythroid mass and the possibility of extra medullary hematopoiesis are common for overcome the chronic anemia (25) . Extra medullary erythropoiesis may cause neurological damage such as pressure on the spinal cord and vertebral column. Foot ulcers and incidence of thrombosis are more common in thalassemia intermedia compared to the thalassemia major, especially after splenectomy (26) . normal. The disease can be inherited by β 0 gene (nonsynthetic) and β + gene (synthesis reduced) (12) .
Beta-thalassemia minor
Pathophysiology
Absence or reduce the amount of beta-globin chains cause relative increase of alpha globin chains that are deposited in erythroid precursors in the bone marrow, leading to premature death and therefore an ineffective erythropoiesis. The mutation that reduces the production of beta globin chain is located on chromosome 11. Hemolytic anemia in the environment that causes thalassemia occurs when the insoluble globin chains can cause damage peripheral erythrocyte membrane (27) . The alpha inclusions and degradation products are local for reactive oxygen species (ROS) (17) . When erythrocytes enter peripheral blood due to deposition of alpha tetramers and accumulation of band 3 protein on their surface opsonized by IgG and complement and removed by macrophages and destroyed in the spleen. In these patients, ineffective erythropoiesis lead to anemia and also anemia increase by destruction of peripheral erythrocytes in the spleen. On the other hand, anemia cause hypoxia and hypoxia condition lead to active Hypoxia -inducible factor (HIF) (28) . HIF formed from two unit include αand β that they divorce and inactive in normal oxygen pressure condition but, in hypoxia condition they connect together and active HIF. Activated HIF subsequently increased the EPO. Erythropoietin causes hyperplasia normoblastic and increase hematopoiesis 25 to 30 times with normal and expansion of hematopoietic bone marrow hematopoietic space. This increases the deformation of the bones. As well as long-term and severe anemia and increased of erythroid precursors leading to hepatosplenomegaly and extra medullary hematopoiesis (29) . Erythropoiesis is way to generate mature cells of the hematopoietic stem cells. This process involves several stages of differentiation and proliferation of cells that impress specific expression of erythroid progenitor genes. The process of erythropoiesis occurs through the combined effects of the microenvironment bone marrow and growth factors that increase the survival, proliferation or differentiation of erythroid precursors and nuclear factors that regulate gene transcription. Erythrocyte production is driven by a complex network of transcription factors, which the GATA-1 gene is major gene in erythropoiesis that causes specific upregulation of erythroid genes such as the EPOR, Glycophorin A (GPA) and the globin chains. Proliferation and differentiation of erythroid cells to be positive or negative is strictly controlled to ensure the production of erythrocytes (30) .
Mutations and allelic variants of beta thalassemia
Beta-thalassemia is a heterogeneous on molecular face. Since, have been identified more than 23 different types of molecular defect in the beta-globin gene (31) . Decrease or lake of beta globin chain lead to increase free alpha globin chain that deposit in erythroid precursors in bone marrow so, cause destruction pre-maturation red blood cell and defective erythropoiesis. The degree of reduction globin chain is determined by beta globin gene mutation on chromosome 11.Different strategies classification of genotyping of individuals by categories beta globin gene and cloning of nucleotide sequence led to the identification of several new mutations in the Mediterranean, India, China and America's dark-skinned population (32, 33) .
A number of mutations have been reported in Iran
Generally speaking, IVS -II-1 (G → A) is the most common mutation in Iran (33/9%) of this Mediterranean mutation has high frequency in Iran beside the Mediterranean countries, which may suggest that slope downward East to West that Iran is the origin of this mutation (34, 35) . IVS-I-110 (G → A) is One of the most common alleles of beta thalassemia in Mediterranean countries and, as expected, high frequency of this mutation in the North West of Iran near the Turkish Azerbaijani population has been found and its frequency is reduced in the south east of Iran. On the other hand IVS-I-5 (G → A) is the most common mutation in the Indian subcontinent that is found with high frequency in South and South-East Iran, which is located near Pakistan. While have been found the low frequency of this mutation in the North West of the country. The presence of abundant and dissimilar mutations in Iranian population in category of globin gene, certainly can be as evidence for a method of formation of the population in the past (36) .
Positive regulation of erythropoiesis
The process of erythropoiesis controlled through the combined effects of two major cytokines called stem cell factor (SCF) and EPO. SCF induces the proliferation, survival and reduction differentiation of primary erythroid progenitors and precursors beside basophilic erythroblast stage. EPO is responsible for the proper regulation of hemostatic number of erythrocytes by oxygen in tissues. Interaction between of erythropoietin and erythropoietin receptor leads to activation of JAK2, several signaling pathways involved in kinase Akt, PI3 and STAT5, which inhibits apoptosis, supporting the proliferation of 52 erythroid progenitors and maturation of erythrocytes (37, 38) .
Negative regulator of erythropoiesis through apoptosis
Negative regulator of erythropoiesis is mainly due to cellular apoptosis, a fundamental mechanism for clearing cells that are potentially dangerous. Apoptotic programs realized by the family of proteases that dependent on cysteine and proprietary aspartate, called caspases (39, 40) . (41, 42) . Increased apoptosis is a key feature of ineffective erythropoiesis in beta thalassemia major, so in this case saw an increase in apoptosis erythroid progenitor in the bone marrow, but lymphoid and myeloid precursors don't have increased in apoptosis (43) .
Ineffective erythropoiesis in thalassemia
Despite a significant increase in apoptosis erythroid precursors in the bone marrow in Thalassemia Major, when we see smear of bone marrow, do not see a large addition in number of dead erythroblast. This condition due to cleared by macrophages in the bone marrow (44) . Study of death of apoptotic receptor pathways suggests that the fas and fas ligand express in early and late stages of differentiation together. Both proteins downregulate in the bone marrow or spleen beta thalamic in proerythroblastic cells compared with healthy mice with, which downregulation of fas and fasL may be erythropoietic stress markers. Evidence of conflict inside pathway of apoptosis in thalassemia major doesn't specify to date (45) .
Problems and complications of Thalassemia
Reduction of each globin chains production in Thalassemia, leading to disruption of the relationship between alpha and beta chains. Unpaired chain deposit in red blood cells and this is the beginning of thalassemia problems (44) .
Iron overload
Many of problems create by iron overload and its destructive role in patients with thalassemia. Three main reasons for this phenomenon are considered: ineffective erythropoiesis, frequently blood transfusions and increasing the intestinal absorption of iron, the first and second due to excessive destruction of red blood cells and the latter due to chronic anemia. Addition of iron in thalassemia patients due to the, is the protein transferrin saturation as a carrier of iron in the body, as a result, free iron accumulates in the blood and body tissues, produce potentially harmful compounds in the body tissue (46, 47) .
Cardiac arrhythmia
Heart disorders have been reported as the cause of death in 50% of patients with thalassemia (48) . Two major structural mechanism and cardiac function in patients with thalassemia affects: the accumulation of iron overload in cardiac cells and an increase in cardiac output. The first mechanism causing the myocardial heart and hypertrophy disorders in the heart layers. Impaired function in left ventricular mainly due to this situation (49) . Myocardial sensitivity to oxygen free radical resulting from free iron within the cell in this disorder, thus leads to diastolic dysfunction. The second mechanism caused by the presence of chronic anemia and hypoxia, increase of erythroid cells due to the body's reaction and increase of volume blood. This situation, heart regulate this condition by increase of output but this mechanism lead to pressuring to heart due to increase severity and measure of contraction. Subsequently the mechanism leads to increase pulmonary vascular resistance and consequently increase pressure of pulmonary and resulting right ventricular dysfunction (50, 51) .
Endocrine disorders
Endocrine disorder is from iron overload problems in patients with thalassemia. The anterior pituitary is very sensitive to iron deposition in tissues. This sensitivity can cause serious disturbances in the synthesis and secretion of hormones (52) . In the meantime, hypogonadism is the most common disorder has been observed in 70% of patients with thalassemia (53) . In these patients, product and storage of thyroid hormones is much lower than in healthy people, which combined with delay in puberty, reproductive disorders and related factors (54) . Other complications are reduction of growth access, which causes endocrine disorders involved in its development in patients with thalassemia. Delay or lack of growth during puberty leads to short stature. Other disorders include the primary hypothyroidism, hypoparathyroidism in the second decade of life, 53 decreased ability to build bone and other disorders, osteoporosis and diabetes, in these patients (55) (56) (57) .
Hepatitis
Thalassemic patients receive long-term blood and blood products and are at risk of viral infection such as viral hepatitis. Despite hepatitis B vaccines for donors and thalassemic patients, the prevalence of these viral diseases among these patients is greatly reduced (58) . But the lack of a vaccine for hepatitis C, continuously, it's a greatly difficult among these patient.
Osteoporosis
Almost all thalassemic patients are suffering from this condition. The consequences of osteoporosis can be noted multiple fractures and severe bone pain. Since the mineral density of axial bone occurs faster than peripheral bone in adulthood, lumbar vertebra spine are affected more than other sectors (59, 60) .
Treatment
Change of expression and production of HbF
Replacing HbA to HbF formed short time after birth in human due to change production gamma gene to beta-globin gene is. This process requires specific class changes in the expression or function of transcription factors and reconstruction chromosomes activities in gene repression expression of gamma globin and induce beta globin gene (61) . Increase HbF able to improve the clinical symptoms in patients with thalassemia. As well as, increase HbF lead to reduce balance between alpha and beta chain (due to beta chain production is plague) this results reduction of red blood cell destroyed (62) . Some chemicals and drugs such as Hydroxia Urea (HU) can induce synthesis of fetal hemoglobin in adults. Studies show that HU treatment was effective on increasing gamma globin and effective for beta-thalassemia and improve clinical and hematological symptoms in thalassemia intermedia (63, 64) .
Hematopoietic stem cell transplantation
Stem cell transplantation is an accepted treatment for thalassemia major (65) . In this treatment, stem cells isolated from the bone marrow of healthy individuals, transferred to patients this method is used in the treatment of many diseases such as thalassemia. The treatment was successful in nearly 80 percent of transplant recipients (66) . The way to find eligible donor, is examined with transplant recipients according to human leukocyte antigens (HLA). What more agreeable between them, success increases in transplantation and don't reject it. But the most important and dangerous problem in bone marrow transplantation called graft versus host disease (GVHD), which in the end leads to death in transplant recipients (67, 68) .
Maintenance Treatment
Chelators therapy
One of the main treatments is for patients who receive blood. These factors play an important role in Back toxicity of Iron overload is. However, these drugs can produce side effects on the nervous system, their smell and hearing. The intravenous chelating can be noted deferoxamine and oral chelating such deferiprone (69) .
Induction of fetal hemoglobin production
It is observed that people with fetal hemoglobin expression is long term, increases lifespan of red blood cells. This forms the basis of this type of treatment. The following drugs have been used for this purpose (70) .
Hydroxiaurea
The first effects of hydroxyurea were found in patients with sickle cell disease (71) . After discovering the fact that hydroxyurea increased gamma-globin it was used in the treatment of thalassemia (72) . Hydroxyurea is a ribonucleotide reductase inhibitor and act as a cytotoxic agent for synthesis phase of the cell cycle (73) . For the treatment of sickle cell anemia has been tested successfully. It acts as increasing fetal hemoglobin for treatment. Studies of several center determine to use hydroxyurea, is reduced period of bedridden due to acute pain of thorax and necessity to blood transfusion in sickle cell anemia. After two years of treatment beginning, the total amount of fetal hemoglobin increases from 5% to 9% in the majority of patients. Along with increasing fetal hemoglobin, decreases sickle hemoglobin polymerization rate. At 9 years of follow-up, 233 cases were identified by medical examiner, has decreased that up to 40% of deaths. Several different mechanisms have been proposed to increase fetal hemoglobin (74, 75) .
Since hydroxyurea destroys terminal progenitor cells directly and produce erythroid cells rapidly. So it is suggested this is due to impaired maturation of erythroid precursors. Accelerated hematopoietic causes to increase the immature line commitment and induce the formation of cells contain hemoglobin fetus. Hydroxyurea increases the amount of erythropoietin and progenitor cells can be induced proliferation. The mechanism of action listed for Hydroxyurea can be included in this category (76, 77) . It is reported that increased fetal hemoglobin 54 expression may be due to increased expression of GATA-2 and reduction of expression of GATA-1. Hydroxyurea could also lead to regulation of gene expression related to cell cycle and apoptosis (78) . Hydroxyurea performance is related to its concentration. Induction of peroxidation by hydroxyurea can induce nitric oxide (NO). Nitric oxide is a known inducer soluble guanylate cyclase. This plays a role in increase in fetal hemoglobin (79) . A GTP-binding protein called SAR specified as inductive particular gene is regulated under Hydroxyurea (78, 80) .
Factors of hypo-methylation
These compounds, such Azacytidine compounds also caused switch adult hemoglobin to fetus but as butyrate and hydroxyurea have much their clinical side effects, especially Azacytidine is a major core structural change (81). 5-Azacytidine is first type of agents known to increase fetal hemoglobin. These drugs do their activity through gene silencing in epigenetic (82) . The drug was used as an anti-cancer agent for the first time in the United States in the '70s, then, it was applied in patients with hemoglobin disorders in the '80s (83) . already used as a treatment for MDS patients (84). 5-Azacytidine has ability to stimulate the production of fetal hemoglobin in anemia monkey was studied for the first time. This was associated with an increased 70-80 percent of total hemoglobin. This study became basis for other studies that hypometylasion DNA can be used as a setup for expression of fetal hemoglobin in vivo function. This successfully data provide clinical trial studies to use to treat for hemoglobin disorders. In patients with sickle cell and thalassemia, treatment lead to a significant increase in the amount of fetal hemoglobin. This manifests 7 to 23 percent increase in fetal hemoglobin, 11 to 50 percent of cells containing fetal hemoglobin and total hemoglobin 1 to 4 grams per deciliter, respectively. Therapeutic effects were associated with the reduction of sickle cells in sickle cell anemia, reduction of imbalances chains β, α, and decrease the need for blood transfusions in beta-thalassemia. Despite the promising data from experimental clinical studies were not continued, because shall be considered some carcinogenic effects of this matter. Tumors have been demonstrated in animal models (61, 85) .
Hemin
In vitro Hemin stimulates the production of hemoglobin fetus. Which can cause side effects such as phlebitis (inflammation and spasm in veins) noted (86) .
Antioxidants
Free radicals play a role in the pathophysiology of damage to the red blood cell membrane. The use of antioxidants can block the effect. The release of small amounts of iron may trigger oxidation-reduction reactions and reduced regenerative capacity of cells. The use of vitamins C and E as antioxidant have been studied greatly (87) .
Immunomodulator agents
Pomalidomide and Lenalidomide can be increased gamma gene expression without any cytotoxic effect other the inducer compounds. In fact, these two drugs are immunomodulatory drugs that reduce the production TNF-α. Pomalidomide induce the production of hemoglobin F stronger than other drugs. It has epigenetic effects like Butyrate (88) . It doesn't cause increase expression of the alpha gene that is very important in thalassemia patients. Thalidomide is an Immunomodulatory drug, which is main treatment in multiple myeloma and has good effects on induction of hemoglobin F and it has mechanisms similar to previous two drugs (89) . Of course, this drug has a strong teratogenic and this is limited in application (90, 91) .
Molecular Therapy
Due to the adverse effects of drugs in increase HbF, new therapeutic approach suggest to increase in hemoglobin F, which includes molecular targets for induction of alpha hemoglobin F. In fact, this therapeutic approach bears, molecules that play a role in regularity expression gene hemoglobin F and class switching beta chain and require to correctly understand these pathways. Here described some of the molecules (92).
B-Cell Lymphoma / Leukemia (BCL11A)
This involve as a growth factor in the production of Blymphocytes. This factor has a low expression when erythroid cells greatly express gamma chain and hemoglobin F in embryonic early hematopoiesis and liver hematopoiesis (93) .
This factor silences gamma chain by banding to GATA-1 and NURD set. In fact, these factors have a direct role in the class switching gamma to beta chain and silencing the expression of the gamma chain (94) . Inhibition of its expression using siRNA in blood progenitor cells in adults cause to increase the expression of hemoglobin F (95).
EKLF.1
It is a major factor in the maturation of red blood cells. This factor normally sticks CACCC sequences in the globin promoter region and increases its expression and silencing gamma chain and class switching the chain of gamma to beta (93, 96) . Two methods include direct and indirectly through the increased expression of BCL11A and thus silencing gamma chain (95) . So, inhibition of this factor by siRNA can be increased HbF.
SOX-6
A factor that normally plays a role in erythropoiesis and the silencing of gamma chain by siRNA that increased gamma chain (97) .
MYB
it is a requirement factor in normal erythropoiesis that reduces expression gamma chain. Increased expression of MYB in K-562 cells resulted in decreased expression of the gamma chain. In trisomy 13 was also referred to the relationship MYB and hemoglobin F. The disease has been found that increased expression of HbF associated with increased expression of miR-15a/16-1, which increase expression of microRNA lead to direct inhibition MYB and increase HbF (70, 98) .
Ikaros
It is a factor that is predominantly expressed in hematopoietic cells in adult. This factor is in PYR set and it has a role as sub-units binding this set to DNA, silencing gamma chain and switching gamma to beta and. Lack expression of Ikaros (IK -/-) lead to increase expression HbF in mice (99) .
Direct Repeat Erythroid Definitive (DRED)
This factor is formed from two subunits, TR2 and TR4. This factor has a high binding affinity to DR-1, the alpha and gamma globin in the promoter region, and has the inhibitory effect and lead to off the two chains, but the promoter of beta globin is lacking in this place. As a result of inhibition of this factor using SiRNA can be increased HbF (100).
Stage Selector Protein (SSP)
This is formed from two subunits, CP2 and P22NF-E4. SSP has a high affinity to connect to the motif SSE in gamma-globin promoter and lead to increase gamma chain expression. Increase P22NF-E4 expression , Increased the expression of gamma chain and the delay in beta-gamma class switching in cell line K562 (101) .
